A few analyst actions in the health stocks: Citigroup analyst Lucy Lu downgrade
(BMRN - Get Report) to hold from buy and lowered her price target to $37 from $42, after surveying 26 treatment centers on Kuvan, a drug for the genetic disorder phenylketonuria (PKU), and subsequently lowering sales and profit expectations.
The stock traded down 3.3% to $34.47.
Also, HSBC Securities downgraded
(NVS - Get Report) to underweight from neutral and lowered its price target to $49 from $52. The stock was off by just 8 cents, or 0.2%, at $50.35.
In other health stocks, Lehman Brothers downgraded
(LPNT - Get Report) to equal-weight from overweight but the stock was seemingly unaffected, adding 83 cents, or 2.9%, to $29.77.
added 39 cents, or 7.4%, to $5.69 after Lehman Brothers analyst Adam Feinstein upgraded the stock to overweight from equalweight, citing new contracts and potential growth despite industry hardships.